Navigation Links
InspireMD Provides Corporate Update, Plans for 2012
Date:1/23/2012

ries: Germany, Hungary, Israel, Poland, Canada, Czech Republic, France, the Netherlands, Ireland, Serbia, Brazil and South Africa. It is actively enrolling patients in 32 centers. The trial's principal investigators are Prof. Alexandre Abizaid, Prof. Dariusz Dudek and Prof. Sigmund Silber. Detailed results from the trial are expected to be submitted for presentations at interventional cardiology meetings in the second half of the year.

Plans for U.S. Registration of MGuard™ Underway

InspireMD is advancing its regulatory strategy for U.S. FDA approval for MGuard™ with a trial that is scheduled to begin in the second half of 2012. This trial will consist of patients undergoing primary revascularization for Acute Myocardial Infarction (AMI) who will be randomized to undergo PCI (Percutaneous Coronary Intervention) with either the MGuard Prime System or the comparator Abbott Vision BMS stent.

The primary efficacy endpoint will be a myocardial blush score of 3, with a successful outcome based on superiority of MGuard™ to the BMS stent. The primary safety endpoint will be non-inferiority Target Vessel Failure (TVF) with secondary endpoints including ST-segment resolution at 60 minutes and MACE at 30 days, 6 and 12 months. Dr. Donald Cutlip, Executive Director of Clinical Investigation at the Harvard Clinical Research Institute, will provide scientific leadership of the FDA Registration trial.

2011 Preliminary Shipment and Revenue Results

Unaudited preliminary shipments of the MGuard™ Coronary Stent system for 2011 increased approximately 78% compared to 2010. Unaudited preliminary revenues for 2011 were approximately $6.0 million, compared to $4.9 million in 2010, an increase of approximately 21%. These numbers have not yet been audited by PWC, InspireMD's external auditors. Final audited numbers for the year will be announced when the Company reports year-end 2011 earnings in March.  <
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Taking its ... all aspects of life, St. Louis’ Sound Mind Café ... better and revolutionized its online presence. Reorganized to highlight ... the new website makes navigating for information and scheduling ... an easily accessible menu-bar in jet black, the cafe’s ...
(Date:8/21/2014)... 2014 According to a recent study ... environmental factors may outweigh genetics in the development and severity ... the world’s population is nearsighted, and this study provides valuable ... is an important finding in the field of ophthalmology,” says ... we finding better ways to treat ophthalmological conditions , ...
(Date:8/21/2014)... While golfing in Scotland and abroad, Biteback ... focused on his game due to the incessant buzzing ... and continual need to spray insect repellent became so ... from insects while golfing. He ultimately found a solution ... Banking Industry, decided to change direction and launch Biteback ...
(Date:8/21/2014)... Denver marketing agency Webolutions® has ... Lung Association in Colorado’s 2014 Run the ‘Rocks ... a sponsor,” said Curt Huber, Chief Development Officer, American ... Lung Association in Colorado, “and we’re eager to see ... they’ve defined.” , Webolutions has also created and is ...
(Date:8/21/2014)... August 21, 2014 HIPAA Secure Now! ... making it possible for EHR vendors to now offer ... requirement for achieving meaningful use. , HIPAA Secure ... to medical practices throughout the U.S. The company assesses ... information (ePHI) from each system and device used by ...
Breaking Medicine News(10 mins):Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2
... September 15, 2008 In a retrospective analysis of ... older, osteoporosis fractures resulted in fracture-related medical expenses of ... presented at the American Society for Bone and Mineral ... analyze the actual long-term fracture-related medical expenses incurred over ...
... more effective than an older conventional antipsychotic in treating ... metabolic side effects, according to a new study funded ... Mental Health (NIMH). The study was published online ahead ... Journal of Psychiatry . , "Schizophrenia and schizophrenia-related ...
... CREEK, Calif., Sept. 14 Longs Drug,Stores Corporation ... it had,received an unsolicited, non-binding expression of interest ... of $75.00 per share in cash,for all of ... and,negotiating a definitive agreement. Longs, Board of Directors ...
... first time, researchers have identified variations in a single ... affecting African-Americans. This work was conducted by researchers at ... investigators at the Johns Hopkins University. The findings are ... Genetics and will be published in the October ...
... 14 Washington State Nurses,Association (WSNA), representing more ... Center (UWMC), held a candlelight vigil to,demonstrate the ... negotiations. The last mediation session is scheduled on ... between Shifts - The Hospital,s proposal to reduce ...
... Understanding Harmful Bacteria Honored with Special Achievement ... ... 13 The 2008 Albert Lasker Medical,Research Awards ( http://www.laskerfoundation.org ) ... nation,s most,distinguished honor for outstanding basic and clinical medical research,discoveries and ...
Cached Medicine News:Health News:Retrospective study analyzes expenses of osteoporosis-related fracture over 3 years 2Health News:Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia 2Health News:Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens 2Health News:Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens 3Health News:Newly found gene variants account for kidney diseases among African-Americans 2Health News:Newly found gene variants account for kidney diseases among African-Americans 3Health News:Newly found gene variants account for kidney diseases among African-Americans 4Health News:Registered Nurses at UW Medical Center Hold Candlelight Vigil to Highlight Concerns for Quality and Safe Patient Care 2Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 2Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 3Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 4
... A necessary addition ... set, the Reichert Trial ... fit and smooth controls ... fitting.,The robust design, high-quality ...
... Master is designed and constructed ... service and give the professional ... procedures. It embodies the characteristics ... most, including accuracy, speed, ease, ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: